ISPOR Leaders Named PharmaVOICE 100 Honorees

Published Aug 2, 2017
Immediate Past-President Professor Lou Garrison and CEO Nancy Berg Recognized as Inspirational Leaders in the Life Sciences Princeton, NJ—August 2, 2017—Two leaders of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) have been named to the renowned list of 2017 PharmaVOICE 100 honorees. Immediate Past-President Lou Garrison, PhD and Chief Executive Officer and Executive Director Nancy S. Berg have been named 2017 PharmaVOICE 100 honorees by PharmaVOICE magazine. Dr. Garrison is Professor Emeritus in the Pharmaceutical Outcomes Research and Policy Program in the School of Pharmacy at the University of Washington. He is a long-term volunteer leader for ISPOR and currently serves in the role of Immediate Past-President. Dr. Garrison is identified as a Change Agent and is described by PharmaVOICE as a global thought leader and teacher in health economics and outcomes research (HEOR) who travels the globe to advance the field. Ms. Berg was recruited in 2014 to head ISPOR, the leading global scientific and educational organization for HEOR. Identified as a Commander and Chief and described as a strategic transformer by PharmaVOICE, Ms. Berg has worked closely with the Society’s Board of Directors to further ISPOR’s mission to advance HEOR excellence to improve decision making for health globally. The PharmaVOICE 100 was established thirteen years ago by PharmaVOICE magazine and is an annual list of inspirational individuals recognized for their positive contributions to the life-sciences industry. The PharmaVOICE 100 honorees represent a broad cross-section of the global life-sciences industry, including pharmaceutical, biopharmaceutical, biotechnology, contract research, clinical trial, research and development, patient education, advertising, digital, marketing, technology, academia, and many other sectors. This diverse group of individuals also represents a wide variety of functional areas ranging from the clinic to the C-suite.

###

  ABOUT ISPOR The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that promotes health economics and outcomes research excellence to improve decision making for health globally. Web: www.ispor.org | LinkedIn: http://bit.ly/ISPOR-LIn | Twitter: http://bit.ly/ISPOR-T (@ISPORorg) | YouTube: http://bit.ly/ISPOR-YT | Facebook: http://bit.ly/ISPOR-FB  

Related Stories

ISPOR Task Force Addresses Critical Gap in Surrogate Endpoint Guidance

May 28, 2026

Value in Health, announced the publication of an ISPOR Good Practices Report providing guidance on the use of surrogate endpoint evaluation methods in health technology assessment (HTA) decision making. The report, “Methods for Evaluation of Surrogate Endpoints for HTA Decision Making: A Good Practices Report of an ISPOR Task Force,” was published in the May 2026 issue of Value in Health.

How Is Health Valued in the United Kingdom? We Finally Have a Better Answer

May 27, 2026

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a pair of companion articles that together establish both the methodological foundation of the first definitive UK value set for the EQ-5D-5L and the practical implications of adopting it—thus equipping health technology assessment decision makers with a UK value set suitable for informing policy. The articles were featured in the May 2026 issue of Value in Health.

ISPOR Announces 2026-2027 Board of Directors

May 26, 2026

ISPOR—The Professional Society for Health Economics and Outcomes Research announced its 2026-2027 board of directors who will assume office on July 1, 2026.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×